T he inflammatory response is a common reaction of the brain parenchyma to ischemia and reperfusion 1 and has been studied systematically by several research groups. Histologically, it is characterized by changes of leukocyte behavior in the microvessels. Many leukocytes roll and adhere to the postcapillary venule and capillary walls; these neutrophils then infiltrate and migrate outside the vascular walls and into the ischemic parenchyma. [2] [3] [4] [5] This inflammatory response is associated with expression of inflammatory mediators, including inflammatory cytokines, 6 chemokines, 7 and adhesion molecules. 8 Our previous studies demonstrated that inflammatory cytokines such as interleukin-1␤ (IL-1␤) and tumor necrosis factor-␣ (TNF-␣) are increased after focal cerebral ischemia and that inhibiting their actions could reduce ischemic brain injury. 9, 10 We have also shown that intercellular adhesion molecule-1 (ICAM-1) is upregulated after ischemia and reperfusion, and this upregulation is associated with the action of IL-1␤ and TNF-␣. 8, 11 However, IL-1␤ and TNF-␣ are poor attractants for polymorphonuclear leukocytes and monocytes/macrophages. C-C chemokines, such as monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1␣ (MIP-1␣), are specifically involved in guiding monocytes/macrophages through the parenchyma and toward the ischemic area. 7, 12 However, few chemokines have been studied in detail in experimental cerebral ischemia.
Transforming growth factor-␤1 (TGF-␤1) has been regarded as an important endogenous mediator that responds to ischemic injury in the central nervous system. 13 Several studies demonstrated that TGF-␤1 mRNA expression was markedly increased during cerebral ischemia and reperfusion. 14 -17 Further studies demonstrated that both in vitro 18, 19 and in vivo 16,20 -22 administration of TGF-␤1 could attenuate ischemic brain injury. However, little is known of the mechanism through which TGF-␤1 acts during cerebral ischemia and postischemic reperfusion. Based on the actions of TGF-␤1 in the brain, the mechanisms through which TGF-␤1 acts may include the following: (1) modulation of the inflammatory cytokine cascade; (2) inhibition of T and B lymphocyte proliferation; (3) an antioxidative effect; and (4) an antiapoptotic effect. Although central or systemic administration of TGF-␤1 reduces ischemic brain injury in shortterm experiments, several limitations are of concern. Activated TGF-␤1 is eliminated from the blood in a few minutes. 23 Providing and maintaining an effective concentration of TGF-␤1 in the brain over a long time is difficult to achieve through systemic administration.
The specific aim of this study is to identify the mechanism by which TGF-␤1 modulates ischemic brain injury. Using a mouse temporary middle cerebral artery occlusion (MCAO) model, we examined whether overexpression of the active human TGF-␤1 (ahTGF-␤1) gene can reduce the expression of MCP-1, MIP-1␣, and ICAM-1 and then reduce ischemic brain injury. A better understanding of the mechanisms through which TGF-␤1 acts may lead to more effective therapies that limit brain injury during ischemia and postischemic reperfusion.
Materials and Methods

Vector Construction and Intracerebral Injection
The construction of AdRSVlacZ, a human adenovirus serotype 5-derived adenoviral vector that transduces Escherichia coli ␤-galactosidase, has been described elsewhere. 24, 25 A recombinant replication-defective (E1, E3 deleted) serotype 5 adenoviral vector was constructed for the overexpression of ahTGF-␤1. The human TGF-␤1 cDNA was generated as described, 26 and both the 5Ј and 3Ј ends of the cDNA were modified with the use of Not 1 linkers. The resulting 2.0-kb ahTGF-␤1 cDNA fragment was cloned into the Not 1 site of the proviral plasmid pAdRSV4. The plasmid pAdRSVahTGF-␤1 was then used to generate recombinant adenoviral clones, as previously described. 27 Individual clones of AdRSVahTGF-␤1 were isolated and subjected to 2 additional rounds of plaque purification before large-scale expansion and purification over CsCl gradients. High-titer stocks of AdRSVahTGF-␤1 were tested in vitro by infection of the TGF-␤1-deficient cell line 159153.2 followed by analysis of cell lysates and conditioned media by enzyme-linked immunosorbent assay (ELISA) (R&D Systems). The conditioned media was also analyzed for biological activity with the CCL4 mink lung epithelial cell DNA synthesis inhibition assay. 28 Purification was done by CsCl banding and desalting over Sephadex G-50; high-titer stocks were stored at Ϫ20°C in PBS containing 5% glycerol and were diluted with complete media or additional PBS immediately before use. The AdRSVlacZ served as a control virus carrying a lacZ gene instead of TGF-␤1.
The institutional animal use and care committee approved procedures for the use of laboratory animals. Mature male CD-1 mice (Charles River, Wilmington, Mass) weighing 30 to 35 g were anesthetized with 4% chloral hydrate (400 mg/kg body wt IP). After induction of anesthesia, the mice were placed in a stereotaxic frame with a mouse holder (Kopf model 921, David Kopf Instruments), and a right burr hole was drilled in the pericranium 1 mm lateral to the sagittal suture and 1 mm posterior to the coronal suture. A 28-gauge needle affixed to a Hamilton syringe was slowly inserted into the right lateral ventricle (3.0 mm deep from dura). One microliter of adenoviral suspension containing 1ϫ10 12 particles per milliliter was injected stereotaxically into the lateral ventricle at a rate of approximately 0.2 L/min. The control animals were injected with the same amount of saline at the same injection rate. The needle was then withdrawn over 5 minutes. The hole was sealed with bone wax, and the wound was closed with a suture. The animals were allowed to recover in their cages.
Human TGF-␤1, MCP-1, and MIP-1␣ ELISA
Over the next 2 weeks, groups of 5 to 7 treated mice were anesthetized with 4% chloral hydrate intraperitoneally, as above, and killed, and their brains were removed. These samples were quickly frozen in liquid nitrogen until the recombinant human TGF-␤1 (rhTGF-␤1) ELISA was performed. The brain was divided into contralateral and ipsilateral hemispheres, and tissue samples were weighed, homogenized in the lysis buffer, and centrifuged at 30 000g for 30 minutes. The supernatants were collected for a commercially available rhTGF-␤1 ELISA (Quantikine, R&D Systems, Inc). All the supernatant samples were assayed in duplicate. The optical density was determined by a microplate reader set to 450 nm with the wavelength set to 540 nm. Authentic rhTGF-␤1 was used to obtain a standard curve.
In addition, MCP-1 and MIP-1␣ concentrations were determined with the use of MCP-1 and MIP-1␣ ELISA kits (Quantikine, R&D Systems, Inc) according to the manufacturer's instructions.
Temporary Middle Cerebral Artery Occlusion
Five days after adenoviral injection, the mice were anesthetized with 1.5% isoflurane in 70%/30% N 2 O/O 2 . A polyethylene catheter (PE-10) was introduced into the left femoral artery for continuous monitoring of arterial blood pressure, sampling of blood gases, and pH analysis. Body temperature was maintained at 37.0Ϯ0.5°C with a rectal temperature probe and a regulated heating pad (YSI model 73ATD Indicating Controller, Yellow Springs Instrument Co). Mean arterial blood pressure was maintained at Ͼ90 mm Hg, and blood gases were analyzed during each anesthesia period. The temporary MCAO method has been described in our previous studies. 29 Briefly, the internal carotid artery was isolated, and the pterygopalatine artery was ligated. Then a 2-cm length of 5-0 rounded nylon (Dermalon) suture with a slightly larger tip was gently advanced from the external carotid artery to the beginning of the middle cerebral artery for a distance of 10.0Ϯ0.5 mm. Reperfusion was performed by partially withdrawing the suture from the internal carotid artery to the common carotid artery. The occlusion lasted for 30 minutes, and reperfusion was maintained for 1, 3, and 7 days. Ischemia production was confirmed by surface cerebral blood flow (CBF) measurement with the use of a laser-Doppler flowmeter (model BPM 2 System, Vasamedics Inc), as described elsewhere. 30 Baseline blood flow recordings of these 3 regions were made 5 minutes before the occlusion. Blood flow values were calculated and expressed as a percentage of baseline values.
Infarct Volume
Three groups of mice (AdRSVahTGF-␤1 transduced, AdRSVlacZ transduced, and saline treated; nϭ8 per group) were killed 1 day after temporary MCAO by decapitation. The brains were removed and frozen immediately in 2-methylbutane at Ϫ42°C for a 5-minute period. Cryostat sections (20 m thick) distal from the frontal pole were cut and mounted on slides. The sections were dried and then stained with cresyl violet. With the use of NIH Image 1.62 software, the ischemic lesion area was calculated as the difference in area of the nonischemic hemisphere and the normal area in the ischemic hemisphere. The infarct volume was calculated by multiplying the infarct areas by the thickness of the sections.
MCP-1 and ICAM-1 Immunohistochemistry
The experimental group design and the brain section preparation were as described above. At specific time points, animals were anesthetized and perfused transcardially with 20 U/mL heparin in 0.1 mol/L PBS (pH 7.4) and 2% paraformaldehyde solution. The brains were quickly removed, post-fixed in 2% paraformaldehyde solution overnight at 4°C, and immersed in 25% sucrose until they sank. The brains were then embedded in Tissue-Tek O.C.T. (Sakura Finetek U.S.A. Inc). Coronal sections (20 m thick) were cut with the use of a cryostat (model CM1800, Leica). Nonspecific binding sites were treated with 15% normal rabbit serum for 30 minutes at room temperature. Sections were incubated with 1:300 dilution of goat anti-mouse MCP-1 antibody (Santa Cruz Biotech) overnight at 4°C.
Normal goat IgG was used as a negative control. After treatment with 1% H 2 O 2 in 30%/70% methanol/PBS solution, the sections were incubated with 1:500 dilution of biotinylated rabbit anti-goat IgG antibody (Vector Laboratory) for 90 minutes at room temperature followed by an ABC process (ABC-Elite Kit, Vector Laboratory). Finally, the sections were treated with stable 3,3Ј-diaminobenzidine tetrahydrochloride (Research Genetics) as a peroxidase substrate. The sections were then rinsed in water, lightly counterstained with hematoxylin, dehydrated through a graded series of alcohols, cleared with xylene, and coverslipped with Permount mounting media.
A double-labeled fluorescent immunohistochemical method was used in this study. After incubation with 5% normal donkey serum containing 2% bovine serum albumin and 0.1% saponin in PBS for 30 minutes at room temperature, the sections were incubated with 1:100 dilution of goat anti-mouse MCP-1 antibody (Santa Cruz Biotech) and 1:100 dilution of rabbit anti-glial fibrillary acidic protein (GFAP) antibody (for astrocytes; DAKO) or 1:100 dilution of rabbit anti-neuron-specific enolase (NSE) antibody (for neurons; Chemicon) overnight at 4°C. After they were washed, the sections were incubated with a 1:50 dilution of fluorescein isothiocyanateconjugated donkey anti-goat IgG (Santa Cruz Biotech) and 1:50 dilution of rhodamine-conjugated donkey anti-rabbit IgG (Santa Cruz Biotech) for 1 hour at room temperature. Double-labeled immunostaining was evaluated with a fluorescence microscope (Nikon Microphoto-SA) with a filter cube (excitation filter, 450 to 490 nm; suppression filter, 515 to 560 nm) for fluorescein isothiocyanate labeling and another filter cube (excitation filter, 515 to 560 nm; suppression filter, 590 nm) for rhodamine. Photomicrographs were obtained by changing the filter cube without altering the position of the section and focus.
The procedure for ICAM-1 immunostaining was the same as for the MCP-1 immunostaining except for the primary antibodies. A rat monoclonal anti-mouse CD54 primary antibody (1:300 dilution; Caltag) was chosen. The total numbers of deep brown-stained ICAM-1-positive vessels were counted in 3 control sections located at ϩ0.86, ϩ0.38, and Ϫ0.10 mm from bregma. The counting was done manually to exclude the infiltrating cells occasionally expressing ICAM-1.
Statistical Analysis
All data are expressed as mean and SEM. Parametric data among the AdRSVahTGF-␤1, AdRSVlacZ, and saline control groups were evaluated with ANOVA followed by Scheffé's between-group comparison (Statview, Abacus Concepts Inc). A value of PϽ0.05 was considered statistically significant.
Results
During the temporary MCAO procedure, the animal's body temperature was kept at 37Ϯ0.5°C. Physiological parameters, including blood pressure, blood PO 2 , PCO 2 , and blood pH, were all kept at normal levels, and there was no difference among the 3 groups (PϾ0.05; data not shown).
TGF-␤1 Expression
The level of rhTGF-␤1 in the mouse brain after AdRSVahTGF-␤1 intraventricular injection was measured by ELISA. In the normal mouse brain, rhTGF-␤1 concentration was undetectable (Ͻ100 pg/g wet wt brain tissue). After cerebral adenoviral transduction, the level of rhTGF-␤1 gradually increased from day 3, peaked at days 7 to 9, and then decreased by day 14. 31 The level of rhTGF-␤1 was also measured in the temporary MCAO mice (Figure 1 ). These mice underwent a single intraventricular injection of AdRSVahTGF-␤1 or AdRSVlacZ or the same amount of saline 5 days before MCAO. There was no statistical difference in the expression of rhTGF-␤1 between the AdRSVlacZ-transduced and the saline control group mice (PϾ0.05), but this expression was slightly higher compared with the control (nonoperated) animals. In the AdRSVahTGF-␤1-transduced mice, the levels of rhTGF-␤1 in the right hemisphere (adenoviral-injected side) were 662Ϯ50, 1455Ϯ60, and 502Ϯ10 pg/g wet wt brain tissue 1, 3, and 7 days after temporary MCAO, respectively. Meanwhile, the levels of rhTGF-␤1 in the left hemisphere (ischemic side) were 839Ϯ107, 1139Ϯ119, and 299Ϯ116 pg/g wet wt tissue at the same time points after temporary MCAO. The rhTGF-␤1 levels in both the ischemic hemisphere and the contralateral hemisphere were similar (PϾ0.05) 1 day after temporary MCAO; however, the rhTGF-␤1 level in the contralateral hemisphere was higher than that in the ischemic hemisphere 3 and 7 days after temporary MCAO (PϽ0.05).
Surface CBF
Surface CBF was measured in the AdRSVahTGF-␤1-transduced, AdRSVlacZ-transduced, and saline control mice after temporary MCAO. CBF in the contralateral hemisphere during occlusion was approximately 90% of baseline CBF. There were no differences among the 3 groups of mice (PϾ0.05). Surface CBF was reduced in both the core (approximately 8% to 10% of baseline CBF) and the perifocal area (approximately 25% of baseline CBF) in all 3 groups of animals at 5 minutes of occlusion. CBF recovered to Ͼ80% of baseline flow after 5 to 10 minutes of reperfusion in both the ischemic core and the perifocal area in these 3 groups of mice. There was no difference between 30 minutes after reperfusion and 1 day after reperfusion (Figure 2; PϾ0.05) . 
Infarction Area and Volume
The infarct areas in the AdRSVahTGF-␤1-transduced, AdRSVlacZ-transduced, and saline control groups 24 hours after temporary MCAO are shown in Figure 3A . The infarct areas in the AdRSVahTGF-␤1-transduced mice on sections 2 to 12 were significantly smaller compared with the AdRSVlacZ-transduced and saline control group mice (PϽ0.05). Infarct volumes in the AdRSVahTGF-␤1-transduced, AdRSVlacZ-transduced, and saline control group 24 hours after temporary MCAO were 14Ϯ1, 21Ϯ2, and 22Ϯ3 mm 3 , respectively ( Figure 3B ). There was no difference between the AdRSVlacZ-transduced and saline control group (PϾ0.05). However, infarct volume in the AdRSVahTGF-␤1-transduced mice was smaller than in the other 2 groups of mice (PϽ0.05). The infarct volume measurements 3 and 7 days after temporary MCAO in these 3 groups paralleled the 1-day post-temporary MCAO group; there were no further reductions observed after a longer reperfusion time.
Expression of MCP-1 and MIP-1␣ in Mouse Brain
The levels of MCP-1 and MIP-1␣ in the brains were determined by ELISA. In the normal brain, the levels of MCP-1 and MIP-1␣ were Ͻ150 pg/g wet wt brain tissue. The levels of MCP-1 and MIP-1␣ were slightly increased in the contralateral hemisphere in the AdRSVahTGF-␤1-transduced, AdRSVlacZ-transduced, and saline-treated groups of mice 1, 3, and 7 days after temporary MCAO. There were no significant differences among the 3 groups (Figure 4A and  4C; PϾ0.05) . The levels of MCP-1 and MIP-1␣ were greatly increased in the ipsilateral hemisphere 1 and 3 days after temporary MCAO in all 3 groups of mice and then gradually decreased (Figure 4B and 4D; PϽ0.05 ). There was no statistical significance between AdRSVlacZ-transduced and saline-treated mice. However, MCP-1 and MIP-1␣ in the AdRSVlacZ-transduced and saline control mice increased more than in the AdRSVahTGF-␤1-transduced mice (PϽ0.05).
Immunohistochemistry showed that MCP-1 immunoreactivity paralleled the ELISA results. Few cells staining positive for MCP-1 were detected in the contralateral hemisphere of the experimental animals after temporary MCAO. The negative control sections showed no immunopositive-staining cells. MCP-1 expression was observed 12 hours after the onset of temporary MCAO in the ipsilateral hemisphere, gradually increased at 24 to 48 hours, and then subsided ( Figure 5A and 5B). Double-labeled immunohistochemical studies revealed that MCP-1 and NSE, and MCP-1 and GFAP were colocalized in neurons and astrocytes ( Figure 5D and 5E). Colocalized positive-stained cells were massively seen in the infarct hemisphere, which indicated that neurons and astrocytes were the sources of MCP-1 during MCAO. Figure 6 showed that expression of MCP-1-positive cells was increased in the ipsilateral hemisphere after 3 days of temporary MCAO. However, the MCP-1 immunopositivestaining cells were attenuated in the AdRSVahTGF-␤1-transduced mice compared with the AdRSVlacZ-transduced and saline control groups. These MCP-1 immunopositivestaining cells were mainly located around the ischemic bound zone and showed neuron and astrocyte morphology.
Immunostaining of ICAM-1
There were a few ICAM-1-positive vessels in the contralateral hemisphere among the AdRSVahTGF-␤1-transduced, AdRSVlacZ-transduced, and saline control groups. The expression of ICAM-1-positive vessels was increased in the ipsilateral hemisphere after 24 hours of temporary MCAO. However, there were no statistically significant differences among AdRSVahTGF-␤1-transduced, AdRSVlacZtransduced, and saline control groups (217Ϯ11 versus 259Ϯ53 and 241Ϯ39, respectively; PϾ0.05). ICAM-1-positive vessels were found in the ischemic core at the early time points after temporary MCAO and in the perifocal region at later time points, probably because of the death of a large number of brain cells at the later time points (Figure 7) . The negative control sections showed no ICAM-1-positive staining.
Discussion
This study demonstrates that (1) the rhTGF-␤1 gene can be locally overexpressed through intraventricular injection of AdRSVahTGF-␤1 and is overexpressed in the mouse brain for 2 weeks; (2) ischemic brain injury is reduced in the AdRSVahTGF-␤1-transduced mice; and (3) inflammatory mediators such as MCP-1 and MIP-1␣ are reduced in the AdRSVahTGF-␤1-transduced mice. These findings suggest that the neuroprotective effect of TGF-␤1 may be related to downregulating inflammatory mediators during temporary cerebral ischemia. Furthermore, AdRSVahTGF-␤1 gene transfer may provide a useful tool in vivo for developing animal models of gene intracerebral transduction.
There are several advantages to introducing the TGF-␤1 gene into mouse brain with the use of an adenoviral vector. Recombinant adenoviruses can transduce multiple types of brain cells, including terminally differentiated cells such as neurons, glial cells, and ependymal cells. 32 The adenoviral vector was injected on the right site of brain rather than the ischemic hemisphere because an inflammatory response to the adenovirus at the injection side might affect ischemic damage. Right intraventricular injection of the transgene resulted in a marked increase of target protein in the CSF or brain tissue. 30, 33 Our previous studies demonstrated the distribution of the lacZ gene (using X-Gal staining) in the AdRSVlacZ-transduced rodent brain. 30, 33 AdRSVahTGF-␤1 gene transfer produces a period of transient TGF-␤1 overexpression (approximately 2 weeks), which parallels the period of ischemic brain injury. 31 As expected, our data show that AdRSVahTGF-␤1 could mediate transient overexpression of rhTGF-␤1 in murine brain. Expression increased at day 1, plateaued at days 7 to 9, and then gradually decreased. Henrich-Noack et al 19 reported that the effect of TGF-␤1 during cerebral ischemia is dose dependent; a single dose of TGF-␤1 (4 ng ICV) shows a neuroprotective effect. In our study the ahTGF-␤1 level was Ͼ1 ng/g brain tissue at 5 days after adenoviral injection and persisted at detectable levels for another 5 days. A relatively low concentration of activated TGF-␤1 may effectively protect the brain from ischemic injury if the rhTGF-␤1 level is maintained for several days. TGF-␤1 was continuously overexpressed 7 days after temporary MCAO, although there was relatively low expression on the first day after temporary MCAO. This result suggests that adenoviral gene transfer can upregulate TGF-␤1 expression even during transient ischemia.
Our data demonstrate that the local overexpression of TGF-␤1 in the brain can reduce infarct volume measured 24 hours after temporary MCAO. Ischemic brain injury alters the pattern of gene expression, including the TGF-␤1 gene. 34 -36 Endogenous TGF-␤1 may play several roles during ischemic Figure 3 . Photographs of brain slices from the saline-treated, AdRSVlacZ-transduced, and AdRSVTGF-␤1-transduced mice after 30 minutes of temporary MCAO with 24 hours of reperfusion with cresyl violet staining revealed no blue staining in the infarct areas. Note that there are fewer infarct areas in the AdRSVTGF-␤1-transduced mice than in the AdRSVlacZ-transduced and saline-treated mice. Graphs show the infarct area (A) and infarct volume (B) in the saline-treated, AdRSVlacZ-transduced, and AdRSVahTGF-␤1-transduced mice after 30 minutes of temporary MCAO with 24 hours of reperfusion. The first slice was cut at ϩ1.54 mm anterior to bregma, and the distance between the slices is 0.3 mm. The infarct volume was calculated by stacking the infarct areas together and measuring at days 1, 3, and 7 after temporary MCAO. Saline indicates saline-treated; lacZ, AdRSVlacZ-transduced; and TGF-␤1, AdRSVahTGF-␤1-transduced mice. Data are meanϮSD; nϭ8 in each group. *PϽ0.05, AdRSVahTGF-␤1 vs saline and AdRSVlacZ groups of mice.
brain injury. TGF-␤1 reduces the activity and function of leukocytes during cerebral ischemia in the rabbit model of thromboembolic stroke. 21 Moreover, TGF-␤1 may regulate inflammatory mediators such as IL-1␤ in the ischemic brain 37 and may also protect neurons from oxidative, apoptotic, and excitotoxic neuronal injury. 19, 38 No differences were observed in physiological parameters after temporary MCAO among the 3 groups, demonstrating that the adenoviral transduction does not cause visible toxic side effects. Surface CBF in the ischemic hemisphere of the AdRSVahTGF-␤1-transduced, AdRSVlacZ-transduced, and saline-treated mice all decreased to approximately 10% of baseline CBF after temporary MCAO, and no significant differences were detected among these groups, confirming our previous observation and suggesting that adenovirus transduction does not affect CBF and that the protective effect of TGF-␤1 during ischemia is not due to higher CBF from inadequate occlusion of the middle cerebral artery.
Focal cerebral ischemia elicits an inflammatory response characterized by the infiltration and accumulation of leukocytes and monocytes/macrophages and the secretion of inflammatory mediators. 39 -41 Chemokines were a new group of chemoattractants focusing on specific leukocyte populations 42, 43 : the C-X-C or ␣-chemokine (IP-10, MIP-2, and IL-8) and the C-C or ␤-chemokine (MIP-1␣, RANTES [regulated on activation, normal T cells expressed and secreted], and MCP1/2/3). The ␣-chemokines showed a special chemoattraction and activation on polymorphonuclear leukocytes, and the ␤-chemokines chemoattract monocytes, lymphocytes, eosinophils, and basophils. 43 MCP-1 is one of the most potent ␤-chemokines for human monocytes in vitro and can induce the secretion of degradative enzymes. 44 Cultured Figure 4 . Concentrations of MCP-1 and MIP-1␣ after 0, 1, 3, and 7 days of temporary MCAO in sham, saline-treated, AdRSVlacZtransduced, and AdRSVahTGF-␤1-transduced mice. One microliter of AdRSVahTGF-␤1 was injected into the right lateral ventricle, and the left side of the middle cerebral artery was occluded 5 days later. Inj indicates immediately after adenoviral vector injection; 0d, 0 days of MCAO, that is, 5 days of adenoviral vector injection; saline, saline-treated; lacZ, AdRSVlacZ-transduced; and TGF-␤1, AdRSVahTGF-␤1-transduced mice. The concentrations of MCP-1 and MIP-1␣ (pg/g wet wt tissue) were determined by ELISA. MCP-1 (A) and MIP-1␣ (B) levels in the contralateral hemisphere were low, and there were no significant differences among the 3 groups. However, the levels of MCP-1 (C) and MIP-1␣ (D) in the ipsilateral hemisphere were significantly increased after 1 and 3 days of temporary MCAO. After 7 days of temporary MCAO, all levels were decreased. Data are meanϮSD; nϭ4 to 6 in each group. *PϽ0.05, AdRSVahTGF-␤1 vs AdRSVlacZ or saline groups of mice. 
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human fetal microglial cells and astrocytes can produce MCP-1 when stimulated by lipopolysaccharide, IL-1␤, and TNF-␣. The microglial cells also show increased migratory response to the ␤-chemokines. 45 Gourmala et al 46 reported that MCP-1 mRNA was present in rat astrocytes surrounding the ischemic tissue between 6 hours and 2 days after MCAO. After 4 days, MCP-1 mRNA was found in macrophages and microglial cells in the infarct tissue. Wang et al 47 demonstrated that MCP-1 mRNA increased in the rat brain with temporary MCAO or permanent MCAO at 6 hours and peaked between 12 and 48 hours; increased MCP-1 protein expression was still detectable 5 days after permanent MCAO. Kim et al 48 found that both MCP-1 and MIP-1␣ mRNA were weakly expressed at 6 hours, peaked at 2 days, and were markedly attenuated at 4 days after MCAO.
Recently, Ivacko et al 49 demonstrated that MCP-1 mRNA and protein expression are increased in the neonatal rat brain after hypoxia-ischemia injury. The temporal profile of MCP-1 expression is in agreement with that of leukocyte accumulation in ischemic brain parenchyma. In these models, polymorphonuclear cells are detected 24 to 72 hours after ischemia, followed at 7 to 16 days by monocyte and macrophage infiltration. 4 However, the expression of MCP-1 protein during ischemia and reperfusion is still not completely elucidated. We identified that neurons and astrocytes appear to be associated with MCP-1 expression during MCAO. MCP-1 immunoreactivity was observed after 12 hours of MCAO, gradually increased at 1 day, peaked at 2 and 3 days of MCAO, then subsided ( Figure 5 ). This result suggests that MCP-1 expression might correlate with necrosis since de- 
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creased synthesis of MCP-1 in the ischemic core could be observed. Increased expression of adhesion molecules has been demonstrated after cerebral ischemia and reperfusion. Several research groups reported that ICAM-1 and endothelial leukocyte adhesion molecule-1 (ELAM-1) are upregulated from 1 to 3 hours up to 1 week after temporary MCAO in rats. 50 -52 In the baboon MCAO model, Okada et al 53 found that ICAM-1 and ELAM-1 upregulated and similarly localized to the endothelium of postcapillary microvasculature in the ischemic penumbra. Another supportive result is the inhibition of endothelial interactions with the leukocyte counterpart of ICAM-1 binding and the reduction in infarct size by 45% to 50% in the rat transient MCAO model. 54 We did not find differences in ICAM-1 expression in the AdRSVahTGF-␤1-transduced, AdRSVlacZ-transduced, and saline-treated mice, suggesting that TGF-␤1 may not regulate ICAM-1 expression during ischemia and reperfusion.
In conclusion, this study describes a close correlation between TGF-␤1 overexpression and neuroprotection against cerebral ischemia and reperfusion. Inflammatory mediators such as MCP-1 and MIP-1␣, but not ICAM-1, are reduced in the rhTGF-␤1-transduced mice, suggesting that TGF-␤1 may play a role in regulating chemokine release and may attenuate ischemic brain injury. However, overexpression of TGF-␤1 may directly reduce infarct volume and thereby reduce chemokine expression as a secondary effect. Proving which is cause and which is effect will require much additional research in the future. On the basis of the potential role of TGF-␤1 as an anti-inflammatory cytokine, these results indicate TGF-␤1 is a novel target molecule for the treatment of stroke and further support a role for inflammatory response in the pathogenesis of stroke.
